Skip to Content

UK Edition. Click here for US version.



View full screen / Print PDF » Download PDF ⇩


Gemzar 200 mg

powder for solution for infusion

Gemzar 1000 mg

powder for solution for infusion


Read all of this leaflet carefully before you start using this medicine because it contains important information
for you.
- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, nurse or pharmacist.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.
What is in this leaflet:
1. What Gemzar is and what it is used for
2. What you need to know before you use Gemzar
3. How to use Gemzar
4. Possible side effects
5. How to store Gemzar
6. Contents of the pack and other information


Gemzar belongs to a group of medicines called “cytotoxics”. These medicines kill dividing cells, including
cancer cells.
Gemzar may be given alone or in combination with other anti-cancer medicines, depending on the type of
Gemzar is used in the treatment of the following types of cancer:
• non-small cell lung cancer (NSCLC), alone or together with cisplatin
• pancreatic cancer.
• breast cancer, together with paclitaxel.
• ovarian cancer, together with carboplatin.
• bladder cancer, together with cisplatin.


Do not use Gemzar:
− if you are allergic (hypersensitive) to gemcitabine or any of the other ingredients of Gemzar.
− if you are breast-feeding
Warnings and Precautions:
Before the first infusion you will have samples of your blood taken to check if your liver and kidneys are working well
enough for you to receive this medicine. Before each infusion you will have samples of your blood taken to check if you
have enough blood cells to receive Gemzar. Your doctor may decide to change the dose or delay treating you depending
on your general condition and if your blood cell counts are too low. Periodically you will have samples of your blood
taken to check how well your kidneys and liver are working.
Talk to your doctor, nurse or hospital pharmacist before using Gemzar.
If you have, or have previously had liver disease, heart disease, vascular disease or problems with your
kidneys talk to your doctor or hospital pharmacist as you may not be able to receive Gemzar.
If you have recently had, or are going to have radiotherapy, please tell your doctor as there may be an early
or late radiation reaction with Gemzar.
If you have been vaccinated recently, please tell your doctor as this can possibly cause bad effects with
If during treatment with this medicine, you get symptoms such as headache with confusion, seizures (fits) or
changes in vision, call your doctor right away. This could be a very rare nervous system side effect named
posterior reversible encephalopathy syndrome.
If you develop breathing difficulties or feel very weak and are very pale, please tell your doctor as this may
be a sign of kidney failure or problems with your lungs.
If you develop generalised swelling, shortness of breath or weight gain, please tell your doctor as this may
be a sign of fluid leaking from your small blood vessels into the tissue.
Children and adolescents
This medicine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.
Other medicines and Gemzar
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including
vaccinations and medicines obtained without a prescription.
Pregnancy, breast-feeding and fertility
If you are pregnant, or thinking about becoming pregnant, tell your doctor. The use of Gemzar should be avoided during
pregnancy. Your doctor will discuss with you the potential risk of taking Gemzar during pregnancy.
If you are breast-feeding, tell your doctor.
You must discontinue breast-feeding during Gemzar treatment.
Men are advised not to father a child during and up to 6 months following treatment with Gemzar. If you would like to
father a child during the treatment or in the 6 months following treatment, seek advice from your doctor or pharmacist.
You may want to seek counselling on sperm storage before starting your therapy.
Driving and using machines
Gemzar may make you feel sleepy, particularly if you have consumed any alcohol. Do not drive a car or
use machinery until you are sure that Gemzar treatment has not made you feel sleepy.
Gemzar contains sodium
Gemzar contains 3.5 mg (< 1 mmol) of sodium in each 200 mg vial and 17.5 mg (< 1 mmol) sodium in each 1000 mg
vial ie essentially sodium free.


The usual dose of Gemzar is 1000-1250 mg for every square metre of your body’s surface area. Your height
and weight are measured to work out the surface area of your body. Your doctor will use this body surface
area to work out the right dose for you. This dosage may be adjusted, or treatment may be delayed depending
on your blood cell counts and on your general condition.
How frequently you receive your Gemzar infusion depends on the type of cancer that you are being treated for.
A hospital pharmacist or doctor will have dissolved the Gemzar powder before it is given to you.
You will always receive Gemzar by infusion into one of your veins. The infusion will last approximately
30 minutes.
If you have further questions on the use of this product ask your doctor or pharmacist.


Like all medicines, Gemzar can cause side effects, although not everybody gets them.
You must contact your doctor immediately if you notice any of the following:
• Bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected
bruising (since you might have less platelets than normal which is very common).
• Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin
than normal which is very common).
• Mild to moderate skin rash (very common) / itching (common), or fever (very common); (allergic reactions).
• Temperature of 38ºC or greater, sweating or other signs of infection (since you might have less white blood cells
than normal accompanied by fever also known as febrile neutropenia) (common).
• Pain, redness, swelling or sores in your mouth (stomatitis) (common).
• Irregular heart rate (arrhythmia) (uncommon)

Gemzar 200 mg

powder for solution for infusion

Gemzar 1000 mg

powder for solution for infusion


The following information is intended for medical or healthcare professionals only:
Instructions for use, handling and disposal.
1. Use aseptic techniques during the reconstitution and any further dilution of gemcitabine for intravenous infusion
2. Calculate the dose and the number of Gemzar vials needed.
3. Reconstitute 200  mg vials with 5  ml of 9  mg/ml (0.9  %) sterile sodium chloride solution for injection, without
preservative, or 25 ml sterile sodium chloride solution for injection, without preservative to the 1000 mg vial. Shake
to dissolve. The total volume after reconstitution is 5.26 ml (200 mg vial) or 26.3 ml (1000 mg vial) respectively. This
dilution yields a gemcitabine concentration of 38 mg/ml, which includes accounting for the displacement volume of
the lyophilised powder. Further dilution with sterile sodium chloride 9 mg/ml (0.9%) solution for injection, without
preservative may be done. The resulting solution is clear and ranges in colour from colourless to light straw-coloured.

Extreme tiredness and weakness, purpura or small areas of bleeding in the skin (bruises), acute renal failure (low urine
output /or no urine output), and signs of infection (haemolytic uraemic syndrome). It may be fatal (uncommon).
• Difficulty breathing (it is common to have mild breathing difficulty soon after the Gemzar infusion which soon passes,
however uncommonly or rarely there can be more severe lung problems)
• Severe chest pain (myocardial infarction) (rare).
• Severe hypersensitivity/allergic reaction with severe skin rash including red itchy skin, swelling of the hands, feet,
ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), wheezing, fast beating heart
and you may feel you are going to faint (anaphylactic reaction) (very rare).
• Generalised swelling, shortness of breath or weight gain, as you might have fluid leakage from small blood vessels into
the tissues (capillary leak syndrome) (very rare)
• Headache with changes in vision, confusion, seizures or fits (posterior reversible encephalopathy syndrome) (very rare)
• Severe rash with itching, blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis) (very rare).
Other side effects with Gemzar may include: (may affect more than 1 in 10 people)
Very common side effects
Low white blood cells
Difficulty breathing
Hair loss
Liver problems: found through abnormal blood test results
Blood in urine
Abnormal urine tests: protein in urine
Flu like symptoms including fever
Swelling of ankles, fingers, feet, face (oedema)
Common side effects (may affect up to 1 in 10 people)
Poor appetite (anorexia)
Runny nose
Muscle pain
Back pain
Uncommon side effects (may affect up to 1 in 100 people)
Scarring of the air sacs of the lung (interstitial pneumonitis)
Wheeze (spasm of the airways)
Scarring of the lungs (abnormal chest X ray/scan)
Heart failure
Kidney failure
Serious liver damage, including liver failure
Rare side effects (may affect up to 1 in 1,000 people)
Low blood pressure
Skin scaling, ulceration or blister formation
Sloughing of the skin and severe skin blistering
Injection site reactions
Severe lung inflammation causing respiratory failure (adult respiratory distress syndrome)
A skin rash like severe sunburn which can occur on skin that has previously been exposed to radiotherapy (radiation recall).
Fluid in the lungs
Scarring of the air sacs of the lung associated with radiation therapy (radiation toxicity)
Gangrene of fingers or toes
Inflammation of the blood vessels (peripheral vasculitis)
Very rare side effects (may affect up to 1 in 10,000 people)
Increased platelet count
Inflammation of the lining of the large bowel, caused by reduced blood supply (ischaemic colitis)
Low haemoglobin level (anaemia), low white blood cells and low platelet count will be detected by a blood test.
You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you
start experiencing any of these side effects.
If you are concerned about any side effects, talk to your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the leaflet. You
can also report side effects directly via
United Kingdom
Yellow Card Scheme
IMB Pharmacovigilance
Earlsfort Centre
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
ADR Reporting
The Medicines Authority
Post-Licensing Directorate
203 Level 3, Rue D'Argens
GŻR-1368 Gżira
By reporting side effects you can help provide more information on the safety of this medicine.


Keep out of the reach and sight of children.
Do not use after the expiry date (EXP) which is stated on the carton and the vial.
Unopened vial: Store below 30°C.
Reconstituted solution: The product should be used immediately. When prepared as directed, chemical and physical
in-use stability of reconstituted solutions of gemcitabine were demonstrated for 24 hours at 30°C. Further dilution
by a healthcare provider may be done. Solutions of reconstituted gemcitabine should not be refrigerated, as
crystallisation may occur.
This medicine is for single use only; any unused solution should be discarded under the local requirements.


What Gemzar contains
The active substance is gemcitabine. Each vial contains 200  or 1000  mg of gemcitabine (as gemcitabine
The other ingredients are mannitol (E421), sodium acetate, hydrochloric acid and sodium hydroxide.
What Gemzar looks like and contents of the pack
Gemzar is a white to off-white powder, for solution for infusion in a vial. Each vial contains 200 or 1000 mg of
gemcitabine. Each pack of Gemzar contains 1 vial.
Marketing Authorisation Holder and Manufacturer
Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL, U.K.
Lilly France S.A.S., rue du Colonel Lilly, F-67640, Fegersheim, France
This leaflet was last revised June 2014

4. Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration.
If particulate matter is observed, do not administer.
5. S
 olutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur. Chemical and physical in-use
stability has been demonstrated for 24  hours at 30°C. From a  microbiological point of view, the product should be used
immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and
would normally not be longer than 24 hours at room temperature, unless reconstitution/dilution has taken place in controlled
and validated aseptic conditions.
6. Gemcitabine solutions are for single use only. Any unused product or waste material should be disposed of in accordance
with local requirements.
Preparation and administration precautions
The normal safety precautions for cytostatic agents must be observed when preparing and disposing of the infusion solution.
Handling of the solution for infusion should be done in a safety box and protective coats and gloves should be used. If no safety
box is available, the equipment should be supplemented with a mask and protective glasses.
If the preparation comes into contact with the eyes, this may cause serious irritation. The eyes should be rinsed immediately
and thoroughly with water. If there is lasting irritation, a doctor should be consulted. If the solution is spilled on the skin, rinse
thoroughly with water.
Any unused product should be disposed of in accordance with local requirements.


Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.